2018-中国医疗改革：谁能生存？（英文版）-5mb

Summary of China's Healthcare Reforms: Who Will Survive?

Core Content

China's healthcare market is projected to grow rapidly, reaching over USD 1 trillion by 2020, with a Compound Annual Growth Rate (CAGR) exceeding 19%. This growth is driven by the country's aging population and rising healthcare costs. The government has launched reforms in 2015 aimed at enhancing the quality, coverage, and sustainability of the healthcare system by moving towards a more decentralized and cost-efficient model.

Main Goals of Reforms

• Reduce healthcare costs by implementing price controls and improving efficiency.
• Develop a more hierarchical system to reduce the overutilization of large level 3 public hospitals.
• Promote the use of general practitioners (GPs) and private healthcare facilities to distribute care more evenly.
• Boost local companies and products in the pharmaceutical and medical device sectors.
• Encourage private health insurance to reduce the financial burden on public funds.

Key Challenges and Impacts

Pharmaceuticals

• Price Pressure: The government is imposing significant price cuts on pharmaceuticals, with some bidding rounds reducing prices by up to 30%. This affects both domestic and multinational companies (MNCs).
• Two Fapiao Invoicing: A new invoicing system requires two invoices for sales, which may reduce margins and challenge companies reliant on smaller distributors.
• Clinical Trial Standardization: All drugs, including foreign ones, must undergo standardized clinical trials, potentially increasing costs and leading to consolidation among domestic firms.
• Transparency in Pricing: The government is pushing for greater transparency in patented drug pricing, which could impact MNCs.

Medical Devices

• Price Pressure: Similar to pharmaceuticals, the government is applying price cuts and promoting local manufacturers.
• Two Fapiao Invoicing: This system may be more challenging for medical device companies due to the need for in-service training and the reliance of smaller distributors on tier 1 financing.
• Support for Local Companies: Policies favor local firms, including faster approval processes and hospital purchasing incentives.
• Disease Group Reimbursement: This system will encourage cost efficiency among healthcare service providers, indirectly affecting device sales.

Healthcare Service Providers

• Decentralization: The government aims to reduce the burden on large level 3 hospitals by promoting a hierarchical system where patients must first visit GPs or lower-level hospitals.
• Private Facilities: Development of private healthcare is encouraged to address unmet needs such as post-op care and rehabilitation.
• Private Insurance: Growth in private insurance is essential for the expansion of private healthcare, as it reduces the reliance on public funds.
• Perception Issues: Public trust in private and GP services remains low, posing a challenge to the success of the decentralized model.

Opportunities for Multinational Companies

Pharmaceuticals

• Innovative Products: MNCs with innovative and unique drug products can still command higher prices and remain profitable.
• Niche Markets: Focusing on selected provinces and profitable products can help MNCs navigate the price pressures.
• Diversification: Combining pharmaceuticals with other healthcare areas like medical devices and telemedicine can create synergies and new profit opportunities.
• M&A Strategy: Acquiring local companies or adopting a multi-brand approach can help MNCs secure market shares and reduce registration costs.

Medical Devices

• Multiple Brands/Products: Offering diverse products and brands can help maintain market presence and brand value.
• M&A: Mergers and acquisitions can provide a pathway to compete with local firms and secure more contracts.
• Overlooked Markets: Patient-pay devices and small but profitable markets offer less competition and potential for MNCs.
• Innovative Products: High-tech and innovative devices will continue to demand a premium in China.

Conclusion

China's healthcare reforms are driven by demographic and financial factors, including an aging population and rising healthcare costs. The reforms aim to create a more sustainable, cost-efficient, and decentralized system. While MNCs face challenges such as price cuts and regulatory changes, they can still find opportunities in innovative products, niche markets, and through diversification and M&A. The long-term success of the reforms will depend on the development of private healthcare and insurance, as well as the ability of local companies to catch up in terms of technology and efficiency.